| abstract |
The present invention disclosed a series of novel selenium-containing isoxazolamine derivatives as shown in formula I, which could regulate the generation and/or activity of TNF-α and ferroptosis-like cell death. The present invention also disclosed the preparation method and the use thereof in preparing a drug for treating the diseases mediated by TNF-α and/or iron-dependent cell death. |